Scarica l'app Stockscreener
2.28
1.30%
-0.03
Pre-mercato:
2.27
-0.010
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte: Revenue Ramp From Symvess Incoming (NASDAQ:HUMA) - Seeking Alpha
Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | H - GuruFocus
Humacyte (HUMA) Phase 3 Trial Highlights Advantages of Engineered Vessel for Hemodialysis | HUMA Stock News - GuruFocus
Humacyte, Inc. Announces the Results from Its V007 Pivotal Phase 3 Clinical Trial of the Acellular Tissue Engineered Vessel - MarketScreener
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - The Manila Times
Phase 3 Trial: Humacyte Vessel Outperforms Standard Dialysis Access in High-Risk Patients | HUMA Stock News - Stock Titan
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in May - Defense World
Nuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Cetera Investment Advisers Buys 9,134 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte (HUMA) to Present Phase 3 Trial Results at Vascular Sur - GuruFocus
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 - TradingView
Breakthrough: Humacyte's Bioengineered Vessel Outperforms Standard Treatment in Phase 3 Dialysis Trial - Stock Titan
Humacyte, Inc. (NASDAQ:HUMA) Shares Acquired by ProShare Advisors LLC - Defense World
BNP Paribas Financial Markets Buys Shares of 14,613 Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DE - Defense World
Deutsche Bank AG Purchases 26,419 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - MSN
Millennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
$HUMA - Binance
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Northern Trust Corp Purchases 92,708 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte (NASDAQ:HUMA) A Risky Investment? - simplywall.st
Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Brokerages - Defense World
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess By Investing.com - Investing.com Nigeria
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess - Investing.com Australia
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - The Manila Times
Humacyte CEO Reveals Latest Bioengineered Tissue Developments at Elite Nasdaq Conference - Stock Titan
Price T Rowe Associates Inc. MD Has $172,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
What is HC Wainwright’s Estimate for Humacyte Q2 Earnings? - Defense World
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock News - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte - TipRanks
Humacyte (HUMA) Receives Continued 'Buy' Rating from Analyst | - GuruFocus
Transcript : Humacyte, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):